Theravance Biopharma, Inc. (NASDAQ: TBPH) today announced positive four-week results from a Phase 2 clinical trial of TD-9855, an investigational ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA Management Comments

Theravance Biopharma (TBPH) Tops Q2 EPS by 44c, Revenues BeatAugust 1, 2018 7:11 AM Theravance Biopharma Reports Positive Top-Line Four-Week Data from Phase 2 Trial of TD-9855 for the Treatment of Symptomatic Neurogenic Orthostatic HypotensionAugust 1, 2018 7:00 AM